SELLAS Life Sciences Group Inc.

News & Events

Press Releases

In The Media

1. SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

   GlobeNewswire APR 28, 2025 8:45 AM EDT
   NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (...
   READ ARTICLE

2. SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

   GlobeNewswire APR 23, 2025 10:23 AM EDT
   NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (...
   READ ARTICLE

3. SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

   GlobeNewswire APR 8, 2025 8:45 AM EDT
   - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (A...
   READ ARTICLE

4. SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

   GlobeNewswire MAR 20, 2025 4:05 PM EDT
   – Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Ga...
   READ ARTICLE

5. Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

   Canada Newswire FEB 27, 2025 10:04 AM EST
   Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 Canada NewsWire ...
   READ ARTICLE

6. Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

   PR Newswire FEB 27, 2025 10:04 AM EST
   Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire ...
   READ ARTICLE

7. SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

   GlobeNewswire FEB 20, 2025 8:45 AM EST
   - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alon...
   READ ARTICLE

8. SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

   GlobeNewswire JAN 28, 2025 3:11 PM EST
   NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ( ...
   READ ARTICLE

9. SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

   GlobeNewswire JAN 23, 2025 8:10 AM EST
   - REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and...
   READ ARTICLE

10. SELLAS Announces Key Business Objectives for 2025

    GlobeNewswire JAN 8, 2025 8:20 AM EST
    - Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in Jan...
    READ ARTICLE